Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.86 +0.77%

+$0.03 today

Market cap
$109.64M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Molecular Partners AGNASDAQ: MOLN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of CHF 12.05M fell 9.1% year over year, behind the -1.7% change in trailing-twelve-month research & development. Sequentially, it rose 4.2% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -9.1% toward the trailing-twelve-month pace of -1.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 12.05M+4.2% QoQ
Last fiscal yearDec 2025
CHF 40.19M-17.3% YoY
LTMMar 2026
CHF 46.97M-1.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.1%——
1 year-17.3%——
3-year CAGR-7.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

CHF · from the income statement

Latest · FY2025
40.19M CHF
Year-over-year change
-17.3%
4-year CAGR
-7.8%

Research & Development vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.7% is the 3rd highest of 9, against a peer median of -23.2%.
  • Over three fiscal years its annual growth of -7.5% compares with a peer median of +4.5%.
MOLN Competitors
Research & Development for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$114.68M USD-37.7%-16.4%622.7%
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$18.8M USD-26.8%-18.0%593.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding MOLN) —-23.2%+4.5%775.6%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.